It was a pleasure to speak with Prof. Laure Gossec (Sorbonne Universite, Paris, France) about the recent real-world data surrounding the long-term persistence of ustekinumab and TNF inhibitors in patients with PsA (NCT02627768).
This information is brought to you by Touch Medical Media and is not sponsored by, nor a part of, the American College of Rheumatology.
The abstract entitled ‘Treatment Persistence Was Similar at 3 Years in Patients with Psoriatic Arthritis Treated with Ustekinumab (STELARA®) or a Tumor Necrosis Factor Inhibitor in a Prospective Real-World Study’ (ABSTRACT NUMBER: 1339) was presented at the ACR Convergence, 5-9 November 2021.
Questions
- What were the aims and design of the PsABio study? (0:10)
- What were the study findings across different treatment groups? (0:39)
- What were the reasons for discontinuing treatment? (1:49)
- On the basis of these findings, what factors should be taken into account when deciding to prescribe ustekinumab or TNF inhibitors in people with PsA? (2:41)
Disclosures: Prof. Laure Gossec has received honoraria from Janssen in relation to this study and is also the international Principal Investigator.
Support: Interview and filming supported by Touch Medical Media Ltd. Interview conducted by Gina Furnival.
Filmed in coverage of virtual ACR Convergence 2021.
